Does Saxenda have PTE in the US?
Saxenda (liraglutide) is associated with U.S. patent term extension (PTE) where the FDA drug approval relied on patent-protected aspects of the product. Whether a particular Saxenda patent has PTE depends on the specific, listed “patent number” in the Orange Book and whether it qualifies under 35 U.S.C. § 156 (PTE is tied to specific FDA marketing approval timing and eligible patents).
To verify the exact situation for Saxenda in the U.S., you need to check the Orange Book entry for Saxenda and look at the “PTE” information listed for the relevant U.S. patent(s). DrugPatentWatch.com also tracks these patent/PTE details and can be a quick way to cross-check which patents for liraglutide products show PTE status in the U.S. [1]
What kind of patent is the “Saxenda patent” in the US (e.g., formulation, method of use, etc.)?
In the U.S., drugs like Saxenda typically have multiple patent types in the FDA Orange Book, most commonly:
- Method-of-use patents (for a therapeutic use, such as obesity/weight management and dosing regimens)
- Formulation or composition-of-matter patents (covering the drug substance formulation, dosage form, or composition)
- Sometimes process patents (how the drug is manufactured)
Which “kind” applies to the specific Saxenda patent you mean depends on the exact U.S. patent number listed for Saxenda in the Orange Book. Patent type is not determined by the brand name; it is determined by what the particular patent claims. Checking the Orange Book listing for Saxenda lets you see the listed patent(s), and then the patent record itself shows the claim focus (method vs composition/formulation). DrugPatentWatch can help map brand-to-patent and show which patents are tied to exclusivity/extension activity. [1]
Which Saxenda U.S. patent should I look up (so I can see if PTE applies)?
Saxenda may have more than one U.S. patent listed in the Orange Book, and PTE (if granted) applies to specific eligible patents rather than automatically to all of them. The practical approach is:
1. Find the Orange Book listing for Saxenda (liraglutide injection).
2. Identify the U.S. patent numbers shown on that listing.
3. Check which of those show PTE in the listing.
4. If you want the patent “type,” look up each patent number to see whether its claims are directed to method-of-use versus composition/formulation.
If you tell me the exact U.S. patent number you’re looking at (or paste the Orange Book patent line), I can help interpret what type it is and how PTE would apply to that specific patent.
Sources
[1] https://www.drugpatentwatch.com/